Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mapc treatment of brain injuries and diseases

a brain injury and disease technology, applied in the field of brain injury and disease treatment, can solve the problems of brain injury, including brain diseases, major health problems, focal hypoxia, cortical infarcts and strokes, etc., and achieve the effect of safe storag

Active Publication Date: 2018-05-03
ABT HOLDING COMPANY +1
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Brain injuries, including brain diseases, are a major health problem both in the US and worldwide.
Focal hypoxias can lead to, for instance, cortical infarcts and stroke.
HI injury and its related outcomes affect a significant number of live births every year.
Measuring the incidence and effects of ischemic and hypoxic brain injury in children is complex; but, the number of patients affected is large by any assessment.
The current overall clinical outcome of term infants with HI injury is poor.
Other than supportive care, therapy for HI injury is limited.
However, the usefulness of the therapy appears limited to the period shortly after birth.
The lack of therapy, number of affected individuals, coupled with the costs necessary to facilitate care and rehabilitation for life, indicate that HI injury represents a current, significant, unmet medical need.
Stem cells derived from adult tissue have been of limited value because they are immunogenic, have limited differentiation potential, and have limited ability to propagate in culture.
For this reason, there is pessimism about their utility in clinical applications, despite their advantageously broad differentiation potential.
Stem cells derived from embryos also are subject to ethical controversies that may impede their use in treating disease.
Accordingly, these types of stem cells are, inherently, limited in their therapeutic applicability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mapc treatment of brain injuries and diseases
  • Mapc treatment of brain injuries and diseases
  • Mapc treatment of brain injuries and diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

Hypoxic-Ischemic Injury with MAPCs in Rats and Treatment with MAPCs and Immunosuppression

[0257]Seven day old Sprague Dawley (SD) rat pups (n=7 per test group) were subjected to HI injury by the method of unilateral carotid ligation followed by 8% hypoxia, as described in Rice et al., Ann Neural. 9: 131-141 (1981), which is herein incorporated by reference in its entirety particularly in regard to this method. Seven days after the injury, the animals underwent stereotaxic transplantation into the hippocampal region with cryopreserved MAPCs (thawed just prior to transplantation) derived from either SD rats (syngeneic, GFP-labeled, 200,000 cells per animal) or Fisher rats (allogeneic, β-gal-labeled, 200,000 cells per animal). All animals were treated with daily immunosuppression (CSA, 1 mg / kg, i.p.) throughout the survival period. On days 7 and 14 post-transplantation, the Elevated Body Swing Test (EBST) and Rotarod test were performed to reveal general and coordinated motor and neurol...

example 2a

Evaluation of Locomotor Skills at 7 and 14 Days After MAPC Injection in HI-Injury Rats

[0258]Animals were treated as described in Example 1. At day 7 post-transplantation, MAPC transplanted HI injured animals displayed a trend of less motor asymmetry as determined by the EBST (64%-65% versus 75%) and longer time spent on the rotarod (14.1-16.5 versus 18 seconds) compared to vehicle-infused injured animals. At day 14 post-transplantation, MAPC transplanted animals exhibited significantly reduced motor asymmetry (66%-70% versus 87%) and longer time spent on the rotarod (27.3-28.3 versus 21 seconds) than those control animals that received the vehicle infusion. Syngeneic and allogeneic MAPCs transplanted into injured animals did not differ statistically in their behavioral improvements at both test periods. Results are depicted graphically in FIG. 2. The results show the therapeutic effects of injected MAPCs in the rat HI injury model by both locomotor and neurological measures.

example 2b

Histological Analysis of MAPC Engraftment on Day 14 after MAPC Injection in Brains of HI Rats

[0259]Animals were treated as described in Example 1. Grafted MAPCs were detected in the brains of the HI-injured animals after sacrifice on Day 14 post transplantation by histological examination. GFP-positive syngeneic grafts were detected mostly in the original hippocampal CA3 transplant site and adjacent CA2 region, which co-labeled with DAPI. Allogeneic grafts, detected by anti-β-gal staining and co-labeling with DAPI, displayed a similar pattern of graft survival in HI injured brains. Graft survival was 0.96% at 14 days (ANOVA F value is 24.27, df=2, 19 and p<0.0001; Fisher posthoc is p<0.0001). The results show that both allogeneic and syngeneic MAPCs engraft at the injection site and persist to at least two weeks after direct intracerebral injection in animals in the rat HI injury model.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thickaaaaaaaaaa
massaaaaaaaaaa
cell massaaaaaaaaaa
Login to View More

Abstract

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

Description

REFERENCE TO RELATED APPLICATIONS[0001]The present application claims priority of and incorporates by reference in their entireties each and all of the applications whose serial numbers are enumerated below:[0002]U.S. Provisional Application Ser. No. 60 / 760,951 filed on Jan. 23, 2006 of which the present application is a continuation-in-part application; PCT / US / 43804 filed on 9 Nov. 2006 of which the present application is a continuation-in-part application and which is a continuation-in-part application of U.S. patent application Ser. No. 11 / 269,736 filed on 9 Nov. 2005, which is a continuation-in-part of U.S. application Ser. No. 11 / 151,689 filed 13 Jun. 2005, which is a continuation in part of U.S. application Ser. No. 10 / 963,444 filed 11 Oct. 2004 (abandoned), which is a continuation-in-part of U.S. application Ser. No. 10 / 048,757 filed 1 Feb. 2002, which is a U.S. national stage application of PCT / US00 / 21387 filed 4 Aug. 2000 and published in English as WO 01 / 11011 on 15 Feb. 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K35/50A61K38/13A61K35/48A61K35/44A61K35/407A61K35/30A61K31/4353A61K35/12A61K31/661A61K31/52A61K31/485A61K31/436A61K35/28
CPCA61K35/50A61K38/13A61K35/48A61K35/44A61K35/407A61K35/30A61K35/28A61K35/12A61K31/661A61K31/52A61K31/485A61K31/436A61K31/4353A61P25/00A61K2300/00A61K35/51A61K35/545
Inventor MAYS, ROBERTDEANS, ROBERT J.HESS, DAVID C.CARROLL, JAMES E.BORLONGAN, CESAR V.
Owner ABT HOLDING COMPANY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com